Genetic Aspects of Drug Disposition and Therapeutics
- 1 February 1992
- journal article
- review article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 32 (2) , 107-117
- https://doi.org/10.1002/j.1552-4604.1992.tb03814.x
Abstract
No abstract availableThis publication has 70 references indexed in Scilit:
- Recent Developments in Hepatic Drug OxidationClinical Pharmacokinetics, 1990
- Nifedipine: Variability in its kinetics and metabolism in manPharmacology & Therapeutics, 1989
- Pharmacokinetics of Nifedipine Slow Release Tablet in Mexican Subjects: Further Evidence for an Oxidation PolymorphismThe Journal of Clinical Pharmacology, 1989
- S-METHYLATION IN MOTORNEURON DISEASE AND PARKINSON'S DISEASEThe Lancet, 1989
- A human cytochrome P-450 is recognized by anti-liver/kidney microsome antibodies in autoimmune chronic hepatitisBiochemical and Biophysical Research Communications, 1989
- Genetically Determined Variability in Acetylation and Oxidation Therapeutic ImplicationsDrugs, 1985
- Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism) — Increased michaelis constant (km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizersBiochemical and Biophysical Research Communications, 1984
- Ethnic Differences in Drug MetabolismClinical Pharmacokinetics, 1982
- Defective Oxidation of DrugsClinical Pharmacokinetics, 1982
- Hypotensive response to debrisoquine and hydroxylation phenotypeLife Sciences, 1978